# nature portfolio

Corresponding author(s):	Peter Soba
Last updated by author(s):	Oct 31, 2023

### **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

				•
< ⋅	トつ	1	ıct	100
. )	ıa	ш	เรา	ics

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	$\square$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🔀 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	🔀 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
$\boxtimes$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
$\boxtimes$	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
$\boxtimes$	$\square$ Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

#### Software and code

Policy information about <u>availability of computer code</u>

Data collection

ZEISS ZEN Blue Software, FIMtrack software (https://github.com/kostasl/ FIMTrack); MicroWin (plate reader); Trikinetics activity monitor;optoPAD (https://github.com/ribeiro-lab/optoPAD-software)

Data analysis

Prism 8.0; Fiji package (ImageJ v2), StackReg (Fiji plugin); TimeSeries AnalyzerV3 (Fiji Plugin); actogramJ (Fiji plugin); FIMTrack software ((https://github.com/kostasl/ FIMTrack); Matlab 2022b

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The raw data generated in this study are provided in the Source Data file. The raw imaging data (calcium imaging and immunohistochemistry) generated in this study can be obtained by request from the corresponding author. Source data are provided with this paper.

D		1	participants	market at the following		l:	
RESEARCH	In\/\n\\/Ing	nııman	narticinants	Their data	or nio	INGICA	i materia
11C3Carcii	III V OI V II I E	Halliali	participants	, tricii aata	, OI DIO	I O S I C G	mattha

		thnicity and racism.				
Reporting on sex	and gender	nd gender n/a				
Reporting on race other socially relegroupings		city, or n/a				
Population charac	cteristics	n/a				
Recruitment		n/a				
Ethics oversight	hics oversight n/a					
Field-spe	_	poal of the study protocol must also be provided in the manuscript.  porting				
Please select the or	ne below that is	the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
Life sciences	Ве	ehavioural & social sciences				
Life scien	ices stu	all sections, see nature.com/documents/nr-reporting-summary-flat.pdf  udy design  points even when the disclosure is negative.				
Sample size		culations were not performed as the effect size was not known before the study. Sample sizes for the different experiments in				
	GPCR assays: 10 larval learning/p adult learning as activity monitor	matched to published experiments that used similar methodology and manipulations1016/j.neuron.2021.03.013 oreference: 10.1038/s41467-018-03130-1 ssays: 10.1371/journal.pbio.3000400 assays: 10.1177/07487304211032336 10.7554/eLife.43924				
Data exclusions	GPCR assays: 10 larval learning/p adult learning as activity monitor feeding assays: No data were ex levels (HEK293 of showed significations)	0.1016/j.neuron.2021.03.013 oreference: 10.1038/s41467-018-03130-1 osays: 10.1371/journal.pbio.3000400 assays: 10.1177/07487304211032336				
Data exclusions  Replication	GPCR assays: 10 larval learning/p adult learning as activity monitor feeding assays: No data were ex levels (HEK293 of showed significat tracking softwar	2.1016/j.neuron.2021.03.013 preference: 10.1038/s41467-018-03130-1 preference: 10.1038/s41467-018-0310-1 preference: 10.10				
	GPCR assays: 10 larval learning/p adult learning as activity monitor feeding assays:  No data were ex levels (HEK293 c showed significat tracking softwar  Representative in replicated in biolegends.	2.1016/j.neuron.2021.03.013 preference: 10.1038/s41467-018-03130-1 preference: 10.1038/s41467-018-03100-1 preference: 10.1038/s41467-01				

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimer	
n/a Involved in the study	n/a Involved in the study
Antibodies	ChIP-seq
Eukaryotic cell lines	Flow cytometry
Palaeontology and ar	———
Animals and other or	ganisms
Clinical data	
Dual use research of	concern
Plants	
Antibodies	
	mouse anti-Rhodopsin (1D4, Cat #MA1-722, 1:1,000, Thermo Fisher)
	rabbit anti-DsRed (Cat #632496, 1:2,000, Takara Bio Inc.)
	mouse anti-GFP (1:2,000, Cat #A-11120, Thermo Fisher) rabbit or guinea pig anti-Discs large (1:30,000 and 1:1.000, Pielage et al. Neuron 2011)
	mouse anti-PDF (PDF C7, DSHB, 1:1000)
	chicken anti-GFP (Cat #ab13970, Abcam, 1:2000)
	2ndary antibodies: donkey anti-mouse Alexa 488 Cat #715-545-150, Jackson Immunoresearch, 1:300
	goat anti-mouse Alexa 546 Cat # A-11030, Thermo Fisher, CA, USA, 1:300
	goat anti-mouse Alexa 488 Cat # A-11001, goat anti-rabbit Alexa 594 Cat # A-11012, goat anti-guinea pig Alexa 647 Cat # A-21450, all 1:1,000; donkey anti-mouse Alexa 555 Cat # A-31570, 1:400; goat anti-chicken Alexa 488 Cat # A-11039, 1:200, all Thermo Fisher
	mouse anti-Rhodopsin: company statement "MA1-722 has been successfully used in Western blot, IHC (P), immunocytochemistry and immunoprecipitation procedures. By Western blot, this antibody detects an ~40 kDa protein representing rhodopsin from Sf9 cells expressing the bovine gene. Immunocytochemical staining of rhodopsin in human retinal samples results in staining of both rod and cone outer segments." (https://www.thermofisher.com/antibody/product/Rhodopsin-Antibody-clone-1D4-Monoclonal/MA1-722) rabbit anti-DsRed: doi.org/10.1073/pnas.1010198107 mouse anti-GFP: This Antibody was verified by Relative expression to ensure that the antibody binds to the antigen stated (https://www.thermofisher.com/antibody/product/GFP-Antibody-clone-3E6-Monoclonal/A-11120) anti-discs large: doi:10.1016/j.neuron.2011.02.007 mouse anti-PDF: doi: 10.1523/JNEUROSCI.0263-05.2005 chicken anti-GFP: doi: 10.1016/j.neuron.2022.10.034
Eukaryotic cell line	es es
Policy information about <u>cel</u>	l lines and Sex and Gender in Research
Cell line source(s)	HEK293T (gift from M. Karsak, ZMNH, University Medical Center Hamburg-Eppendorf), G protein deficient HEK293 cells (deltaG7, Tohoku University, Japan)
Authentication	HEK293T were not further authenticated except for visual inspection, HEK293-deltaG7 cells were functionally tested for the absence of endogenous Gs signaling using the Gsx assay as described in the manuscript
Mycoplasma contaminatio	not tested for HEK293 cells used in this study
Commonly misidentified li (See <u>ICLAC</u> register)	nes  no commonly misidentified cell lines were used in the study,
Animals and other	research organisms
Policy information about stu	dies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in

<u>Research</u>

Laboratory animals

Transgenic Drosophila melanogaster in a w1118 background were used for all experiments. Staged 3rd instar larve (96 h after egg laying) and young adult male flies (1-8d old) were used. The complete list of lines used is shown below. Dop1R1KO-Gal4 UAS-Dop1R1RNAi UAS-Dop1R2RNAi Dop1R2KO-Gal4 201y-Gal4 H24-Gal4 UAS-bPAC UAS-optoDop1R1V2 UAS-optoDop1R2V2 UAS-optoDop1R1V1

ppk-Gal4	
UAS-CsChrimson-GFP	
UAS-Gflamp1	
UAS-Gcamp6s	
MBONg1g2-Gal4	
Pdf-Gal4	
MB011B-Gal4	
2U	
OK107-Gal4	
tub-Gal80ts	
R21B06-splitGal4DBD	
6xCRE-splitGal4AD	
UAS-myr::tdTomato	
UAS-Dop1R1GFP11, UAS-spGFP1-10	
10xUAS-myr::GFP	
No wild animals were used in the study.	

Note that full information on the approval of the study protocol must also be provided in the manuscript.

This study did not require ethical approval.

 $\label{eq:Field-collected samples} \textbf{Field-collected samples} \quad \textbf{No field collected samples were used in the study.}$ 

Wild animals

Reporting on sex

Ethics oversight